WO1998015626A3 - Mutant ciita molecule and uses thereof - Google Patents

Mutant ciita molecule and uses thereof Download PDF

Info

Publication number
WO1998015626A3
WO1998015626A3 PCT/GB1997/002751 GB9702751W WO9815626A3 WO 1998015626 A3 WO1998015626 A3 WO 1998015626A3 GB 9702751 W GB9702751 W GB 9702751W WO 9815626 A3 WO9815626 A3 WO 9815626A3
Authority
WO
WIPO (PCT)
Prior art keywords
ciita
polypeptide
useful
molecule
amino acid
Prior art date
Application number
PCT/GB1997/002751
Other languages
French (fr)
Other versions
WO1998015626A2 (en
Inventor
John William Fabre
Kenth Tomas Gustafsson
Sheng Yun
Original Assignee
Inst Of Child Health
John William Fabre
Kenth Tomas Gustafsson
Sheng Yun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9620940.8A external-priority patent/GB9620940D0/en
Priority claimed from GBGB9705911.7A external-priority patent/GB9705911D0/en
Application filed by Inst Of Child Health, John William Fabre, Kenth Tomas Gustafsson, Sheng Yun filed Critical Inst Of Child Health
Priority to AU45675/97A priority Critical patent/AU4567597A/en
Publication of WO1998015626A2 publication Critical patent/WO1998015626A2/en
Publication of WO1998015626A3 publication Critical patent/WO1998015626A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

A polypeptide that comprises the amino acid sequence of a class II trans activator (CIITA) protein from the N-terminus of which amino acid residues are missing such that the resulting polypeptide reduces the expression of MHC class II antigens is useful in the treatment of autoimmune disease and in the production of transgenic donor animals for xenografts and in the treatment of autoimmune diseases. Ribozymes targeting bases 1159-1161 of human CIITA are also useful, as are nucleic acids encoding the polypeptide and the ribozyme.
PCT/GB1997/002751 1996-10-08 1997-10-08 Mutant ciita molecule and uses thereof WO1998015626A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45675/97A AU4567597A (en) 1996-10-08 1997-10-08 Mutant ciita molecule and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9620940.8 1996-10-08
GBGB9620940.8A GB9620940D0 (en) 1996-10-08 1996-10-08 Mutant ciita molecule and uses thereof
GB9705911.7 1997-03-21
GBGB9705911.7A GB9705911D0 (en) 1997-03-21 1997-03-21 Mutant CIITA molecule and uses thereof

Publications (2)

Publication Number Publication Date
WO1998015626A2 WO1998015626A2 (en) 1998-04-16
WO1998015626A3 true WO1998015626A3 (en) 2000-08-17

Family

ID=26310180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002751 WO1998015626A2 (en) 1996-10-08 1997-10-08 Mutant ciita molecule and uses thereof

Country Status (2)

Country Link
AU (1) AU4567597A (en)
WO (1) WO1998015626A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003250118A1 (en) * 2002-07-19 2004-02-09 Genethor Gmbh Non-antigen presenting cells for selecting t cells
AU2003289907A1 (en) * 2002-11-28 2004-06-18 Genethor Gmbh Cells not presenting antigen for suppressing pathological immune reactions
JP4857450B2 (en) * 2004-03-09 2012-01-18 財団法人名古屋産業科学研究所 Transgenic non-human mammal that reproduces the pathology of human rheumatoid arthritis
GB2434578A (en) * 2006-01-26 2007-08-01 Univ Basel Transgenic animals
JP6095366B2 (en) 2009-06-22 2017-03-15 エスケー バイオファーマシューティカルズ カンパニー リミテッド Methods for treating or preventing fatigue
AU2012217792A1 (en) * 2011-02-14 2013-08-29 Revivicor, Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BONTRON S ET AL: "Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy.", MOLECULAR AND CELLULAR BIOLOGY, (1997 AUG) 17 (8) 4249-58., XP002055140 *
CHANG C H ET AL: "Class II transactivator ( CIITA ) is sufficient for the inducible expression of major histocompatibility complex class II genes.", JOURNAL OF EXPERIMENTAL MEDICINE, (1994 OCT 1) 180 (4) 1367-74., XP002055137 *
CHANG C H ET AL: "Mice lacking the MHC class II transactivator ( CIITA ) show tissue-specific impairment of MHC class II expression.", IMMUNITY, (1996 FEB) 4 (2) 167-78., XP002055135 *
CHIN K C ET AL: "Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 MAR 18) 94 (6) 2501-6., XP002055139 *
RILEY J L ET AL: "Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA).", IMMUNITY, (1995 MAY) 2 (5) 533-43., XP002051560 *
SCHLAEGER T M ET AL: "VASCULAR ENDOTHELIAL CELL LINEAGE-SPECIFIC PROMOTER IN TRANSGENIC MICE", DEVELOPMENT, vol. 121, no. 4, 1995, pages 1089 - 1098, XP000604125 *
STEIMLE V ET AL: "Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).", CELL, (1993 OCT 8) 75 (1) 135-46., XP002051559 *
THE 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY;MEETING SPONSORED BY THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE INTERNATIONAL UNION OF IMMUNOLOGICAL SOCIETIES, SAN FRANCISCO, CALIFORNIA, USA, JULY 23-29, 1995 *
TOTH C R ET AL: "A dominant-negative mutant of the class II MHC transactivator CIITA.", 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY, ABSTRACT BOOK PAGE 695, ABSTRACT 4124, XP002055136 *
YUN S ET AL: "Suppression of MHC class II expression by human class II trans-activator constructs lacking the N-terminal domain.", INTERNATIONAL IMMUNOLOGY 9 (10). 1545-1553., October 1997 (1997-10-01), XP002055141 *
ZHOU H ET AL: "CIITA -dependent and -independent class II MHC expression revealed by a dominant negative mutant.", JOURNAL OF IMMUNOLOGY, (1997 MAY 15) 158 (10) 4741-9., XP002055138 *
ZHOU H ET AL: "Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency.", IMMUNITY, (1995 MAY) 2 (5) 545-53., XP002051590 *

Also Published As

Publication number Publication date
AU4567597A (en) 1998-05-05
WO1998015626A2 (en) 1998-04-16

Similar Documents

Publication Publication Date Title
AU2001278797A1 (en) Expression vector using for animal cell
EP1025840A3 (en) Oral drug compositions and methods
RU93045577A (en) MULTIPLE POLYPEPTIDES
ATE287963T1 (en) PSEUDOMONAS EXOTOXIN - MYELIN BASIC PROTEIN CHIMERIC PROTEINS
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
WO1998015626A3 (en) Mutant ciita molecule and uses thereof
WO2002044197A3 (en) Cytokine receptor binding peptides
RU2214273C2 (en) Dna-sequences encoding human proteins tx and ty relates to enzyme converting interleukin-1-beta
WO1997016549A3 (en) Molecular cloning and characterization of molecules related to relaxin and the insulin family of ligands
EP1233024A3 (en) 25466, a human transporter family member and uses therefor
AU692213B2 (en) Equine arteritis virus peptides, antibodies and their use in a diagnostic test
EE200000478A (en) Peptide, gene encoding it, diagnostic reagent and diagnostic kit, for use in the treatment of rickettsia
EP0378929A3 (en) Membrane proteins and peptides of haemophilus influenzae type b
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
DE68914397D1 (en) Human lymphotoxin.
EP0723016A3 (en) Activating factor of leukocytes
Jorgensen et al. Growth hormone therapy.
WO2002044357A3 (en) Methods of using 18903 to treat pain and pain-related disorders
WO2001090146A3 (en) 57256 and 58289, human transporters and uses thereof
WO2002029041A3 (en) 32146 and 57259, novel human transporters and uses thereof
WO2003008621A3 (en) 87144, human amino acid transporter family member and uses therefor
WO2002059314A3 (en) A human melanoma associated antigen and uses therefor
WO2003091448A3 (en) 696803, a human transporter family member and uses therefor
EP1264843A3 (en) 38554, 57301 and 58324, Human organic ion transporters and uses therefor
DE60234786D1 (en) PEPTIDE BAITS FOR THE MANUFACTURE OF MEDICAMENTS FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES OR PROBLEMS CONNECTED WITH THE OUTCOME OF ANTIBODIES TARGETED AGAINST EXOGENE PROTEINS ARE DETERMINED

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998517308

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG